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Abstract: Gentamicin is readily used for suspected or proven sepsis in neonates, yet it shows considerable inter-individual pharmacokinetic 
variability, which limits achievements of therapeutic levels. Hence, the aim of this study was to compare peak and trough gentamicin 
concentrations according to dosing regimen, to evaluate pharmacokinetic parameters, and to consider adjustments of dosing 
regimen. Babies with infection were treated with 1 h infusion, and daily dose of 5 or 7.5 mg/kg depending on the age. Patients 
were randomized into two groups: I - dosing interval 12 h (n=8), II – 24 h (n=11). Two steady-state blood samples were obtained. 
Pharmacokinetic parameters were calculated using one-compartment model. The results showed a difference (p<0.05) in peak 
gentamicin concentrations between the groups, and tendency of lower trough levels in the group II. Calculated pharmacokinetic 
parameters included the volume of distribution (Vd) 0.52±0.47 l/kg, clearance (CL) 0.055±0.036 l/hkg and a half-life (t1/2) of 
6.89±3.21 h. Based on the method for dosing regimen adjustments, there was a need to extend dosing interval to 36 h in 6 patients. 
  © Versita Sp. z o.o
Keywords: Neonates • Gentamicin • Dosing regimen • Therapy individualization
1 Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade,
  Faculty of Pharmacy, Serbia
2 Institute for Mother and Child Health Care of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
3 Department of Paediatrics, University of Belgrade, School of Medicine, Serbia
4 Department of Pharmacology, Clinical Pharmacology and Toxicology, University of Belgrade
  School of Medicine, Serbia
Katarina M. Vučićević*1, Zorica M. Rakonjac2, Borisav Ž. Janković2,3,  
Sandra D. Vezmar Kovačević1, Branislava R. Miljković1, Milica Š. Prostran4
 Research Article
1. Introduction
Aminoglycosides, particularly gentamicin, are used in 
combination with b-lactam antibiotics for the treatment 
of presumed or proven sepsis in neonates. According 
to the national and international clinical guidelines, gen-
tamicin may be administered via multiple (traditional) 
or once-daily (extended, prolonged interval) dosing 
regimen [1]. Gentamicin is given by repeated slow in-
travenous infusion for 0.5 or 1 h. Multiple daily dosing 
regimen involves administration of 2.5 mg/kg every 24 h 
in neonates <29 weeks of gestation, every 18 h if ges-
tational age is between 29 and 35 weeks or every 12 h 
for neonates >35 weeks of gestation. Once-daily dosing 
regimen involves gentamicin administration of 4-5 mg/
kg every 36 h for patients at <32 weeks of gestation and 
4-5 mg/kg every 24 h for >32 weeks of gestation [1]. 
Exhibition of the post antibiotic effect at drug levels 
below the minimum inhibitory concentration (MIC), lower 
accumulation in the renal tubule and in the inner ear, 
avoidance of the development of bacterial resistance, 
and finally the pharmacoeconomic justification are all 
reasonable grounds to opt for once-daily dosing [2,3]. 
Results of some studies indicate that the administration 
of gentamicin once daily causes minor discrepancies in 
minimal (Ctrough) and/or maximal (Cpeak) concentrations 
from the desired therapeutic range. Based on the results 
of a number of studies, the use of gentamicin by once-
daily regimen in neonates was as effective and safe as 
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traditional dosing [4,5], whereas Croes et al. showed 
restricted nephro- and cochleo-toxicity with preserved 
efficacy upon administration of aminoglycosides once 
daily [6].  
Neonates experience significant and dynamic 
changes in physiological processes that affect the phar-
macokinetic characteristics of gentamicin. Compared 
with the adults, reduced content of fat and muscle tis-
sues, increased percentage of body fluid (70-75% of 
total body weight) and an increased percentage of ex-
tracellular fluid (40% of total body weight) was observed 
[7,8]. Due to hydrophilic characteristics, gentamicin’s 
volume of distribution (Vd) per kilogram of body weight 
is higher (some studies confirmed a two-fold increase) 
in the neonates compared with adults. The average 
values of gentamicin Vd in population of neonates are 
ranging from 0.45 to 0.75 l/kg. Being that gentamicin 
is mainly eliminated by kidney filtration, the glomerular 
filtration rate (physiological parameter of renal function) 
has an essential impact on the values of the gentami-
cin elimination parameters. In neonates, between 28 
and 40 weeks of gestation, glomerular filtration rate is 
30-50% of the value in adults, expressed as a func-
tion of body weight [7]. Renal function matures slowly, 
and depends on gestational and postnatal age. Thus, 
at birth the average blood flow through the kidneys is 
about 12 ml/min and increases up to 140 ml/min in the 
first two years of life [9]. Therefore, clearance (CL) of 
gentamicin is almost entirely dependent on glomerular 
filtration rate, and its values are from 0.53 to 1.72 ml/
min/kg. Elimination half-life (t1/2) is longer than in adults 
with values of 3-11 h [7]. Thus, large inter-individual vari-
ability in the gentamicin pharmacokinetics exists as a 
consequence of gestational age, postnatal age, weight, 
disease characteristics, and co-therapy. These factors 
directly affect the drug concentration in the blood. Thus, 
the value of Cpeak is primarily dependent on Vd, whereas 
Ctrough is primarily influenced by the CL and t1/2. There-
fore, there is a need in the clinical practice to optimize 
the gentamicin-dosing regimen. Being that gentamicin 
exhibits concentration-dependent efficacy and toxicity, 
therapeutic drug monitoring (TDM) is thus a recognized 
approach to individualize dosing regimen [3,10,11]. 
The recommended values for target therapeutic con-
centration  depend upon the dosing regimen. Thus, the 
therapeutic gentamicin Cpeak should be <10 mg/l if the 
drug is given every 12 h, or between 15 and 25 mg/l 
if the dosing interval is every 24 h. The target Ctrough of 
gentamicin is <2 mg/l for drug administration at every 12 
h or <1 mg/l for once daily administration [11].  
The aim of this study was to compare Cpeak and Ctrough 
of gentamicin following a multiple and once daily dosing 
regimens in neonates with ≥37 weeks of gestation, in 
order to assess the gentamicin pharmacokinetic param-
eters and to adjust the dosing regimen.
2. Material and methods
2.1. Patients and therapy
This clinical study was performed in the Pediatric 
Intensive Care Unit and the Neonatal Unit at Pediatric 
Clinic, Institute for Health Care of Mother and Child “Dr 
Vukan Čupić” in Belgrade, Serbia, in the period between 
1st September 2009 and 31st January 2010. The Ethics 
Committee of the Institute has approved the protocol of 
the study, and patients’ parents were informed about the 
purpose and protocol of the study. Written consent was 
obtained before the enrolment.
Previously, diagnosis of sepsis (proven, probable, 
possible, nosocomial) was made according with the rec-
ommendations by the International Sepsis Definitions 
Conference, before initiation of the therapy. The study 
included up to 30 days old neonates with ≥37 weeks 
of gestation, where gentamicin therapy was indicated 
in combination with ampicillin or with third generation 
cephalosporin antibiotics, due to presumed or proven 
bacterial infection. Exclusion criteria comprised: birth 
before 37 weeks of gestation, presence of renal insuf-
ficiency and pre-given antimicrobial therapy.
Data of gestational age, body weight and body length 
at birth were obtained including gender, age and weight 
at the time of admission and Apgar score at 1st and 5th 
minute. In addition, data of maternal age, illnesses dur-
ing pregnancy, status during labor, as well as treatment 
were collected in order to identify potential risk factors for 
the infection. Complete blood tests, C-reactive protein, 
urea, creatinine, β2-microglobulin, serum electrolytes 
and bilirubin levels (where indicated), as well as urine 
analysis were performed in all neonates at admission. 
Cardiac function, respiratory rate/minute, blood pres-
sure and oxygen saturation levels were monitored. Audi-
tory function was also assessed with transient evoked 
otoacoustic emission (TEOAE) method, during first 3 
days, and between 7th and 10th day of treatment.
Gentamicin was administered as 1 h intravenous 
infusion in 5% glucose solution. Patients were randomly 
allocated into one of two groups depending on the dos-
ing regimen: 8 patients received the drug every 12 h 
(group I) and 11 patients every 24 h (group II). Patients 
aged 1-7 days received 5 mg/kg, whereas patients of 8 
days and older received 7.5 mg/kg per day. Two steady-
state blood samples (volume of 0.5-1 ml) were obtained 
from each patient: 1 h after the infusion, and the second 
immediately before the next dose.
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2.2. Bioanalytical, pharmacokinetic and 
statistic analysis
Gentamicin concentrations were measured using a 
validated turbidimetric immunoassay (Thermo Scientif-
ic, UniCel® DxC Synchron® Systems, Beckman Coulter 
Inc., USA).
Based on these data, pharmacokinetic parameters 
for each patient were calculated, applying one-com-
partment linear model based on Sawchuk and Zaske 
method [12]. Elimination rate constant (b), t1/2 and Vd 
were calculated using the following equations:
where τ is the dosing interval, ti is the infusion time, R 
is the rate of drug infusion calculated from the ratio of 
given dose and infusion time. CL was calculated by 
multiplying estimated values of Vd and b.
In order to assess the need for adjustments of dos-
ing regimen, the concept of linear pharmacokinetics, 
recommended gentamicin therapeutic range and calcu-
lated individual values  of pharmacokinetic parameters 
were used.
For descriptive and statistical analysis PASW Sta-
tistics® (ver. 18.0) was applied. Data suitability for spe-
cifi c test was verifi ed. Therefore, use of Student’s t- or 
Mann-Whitney U-test were considered to compare the 
differences in average gentamicin levels or pharmaco-
kinetic parameter values between the groups, with level 
of statistical signifi cance of p<0.05. 
3. Results
Based on the inclusion/exclusion criteria, total of 19 
neonates were enrolled in the study (Table 1). There 
was not a statistically signifi cant difference in the pa-
tients’ characteristics between the groups.
In group I, Cpeak ranged from 5.70 to 9.22 mg/l, while 
in group II we observed levels from 4.84 to 24.62 mg/l. 
Nonparametric test was employed and statistical differ-
ence in the median Cpeak values between groups was 
observed (Figure 1).  Ctrough values in group I ranged from 
0.01 to 2.95 mg/l, while in group II they were between 
0.75 and 2.60 mg/l. Statistical analysis showed that 
there is not a statistical difference in Ctrough values be-
tween groups (Figure 1). The results indicate that Cpeak 
above 10 mg/l was not reached in any of the patients in 
the group I, while in the same group Ctrough was higher 
than 2 mg/l in 4 neonates. Furthermore, in group II, none 
Table 1.  Demographic characteristics of neonatal patients 
CHARACTERISTIC
Gentamicin Dosing Regimen
group I (every 12 h)
(n=8)
group II (every 24 h)
(n=11)
Males 5 (62.50%) 5 (45.45%)
Age 1-7 [days] 6 (75%) 6 (54.54%)
Body weight [kg] 3.13 ± 0.35 3.32 ± 0.31
Body length [cm] 49.88 ± 3.04 50.45 ± 1.81
Apgar score at 1st minute 8 ± 1 8 ± 1
Apgar score at 5th minute 9 ± 1 9 ± 1
Serum creatinine levels on 
1st day of therapy [µmol/l]
75.13 ± 19.76 60.27 ± 25.22
Serum creatinine levels on 
3rd day of therapy [µmol/l]
44.88 ± 9.17 45.18 ± 12.12
Serum creatinine levels on 
7th day of therapy [µmol/l]
43.75 ± 9.24 39.18 ± 7.52
Figure 1.  Inter-quartile range (lower, median, upper quartile) of: a) peak and b) trough gentamicin concentrations depending on the dosing 
regimen.
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of the patients reached gentamicin levels higher than 
25 mg/l, but in 5 patients Cpeak was less than 15 mg/l, 
whereas in 8 patients Ctrough was greater than 1 mg/l. 
Individual values  of pharmacokinetic parameters 
(CL, Vd and t1/2) were calculated from the measured 
gentamicin concentrations. Table 2 shows the results for 
the full population of patients included in the study, and 
statistical difference  between groups was not observed.
In order to assess the need for adjustments of dos-
ing regimen, individual pharmacokinetic parameters 
and recommended therapeutic ranges of gentamicin 
were used. In the studied population, the extended dos-
ing interval from 24 h to 36 h was needed in 6 patients 
undergoing once daily dosing regimen.
The difference was not observed in efficacy and 
toxicity between groups at the beginning and at the end 
of the treatment. In this study, creatinine levels and audi-
tory function did not show marked change by the end of 
the therapy. All the patients were cured by the end of the 
treatment. 
4. Discussion
The results of this study suggest that the use of gen-
tamicin every 24 h in neonates ≥37 weeks of gestation 
has produced significantly higher peak concentrations, 
and there was a tendency for lower trough concentra-
tions compared with twice daily regimen (Figure 1). This 
is in agreement with previously published data [4,13,14]. 
Lower Cpeak could potentially impair the efficacy, due to 
failure in achieving desired ratio of the Cpeak and minimum 
inhibitory concentration (MIC). Routine monitoring of the 
Cpeak is not indicated when gentamicin is administered 
once daily, as it is expected to reach levels above those 
when given twice daily. According to the references, 
therapeutic gentamicin concentration Cpeak is ranging 
from 15-25 mg/l, but it often exceeds 25 mg/l, which is 
not associated with adverse effects on clinical outcome 
[1,15]. However, concentrations below 15 mg/l could be 
linked with the potential inefficiency due to Cpeak:MIC 
ratio <8:1 [3,11]. To confirm this hypothesis, information 
about the local sensitivity of isolated microorganisms 
would be valuable. In this study, in 5 patients Cpeak were 
below 15 mg/l, which is probably due to the high Vd of 
gentamicin, possibly as a result of higher hydration via 
parenteral infusion.
In this study patients on once daily dosing (group I) 
had lower Ctrough compared with group II. These levels 
were slightly higher than recommended range outlined 
above. The results of Cars and Odenholt suggest that 
gentamicin Ctrough may be less than 0.3xMIC when previ-
ously high concentration was observed [16]. Therefore, 
in once daily regimen Ctrough may approximate zero at 
the end of the dosing interval. Our results indicate the 
need to consider adjustments of the dosing regimen in 
individual patients. Accordingly, in the studied neonates, 
extension of the dosage interval from 24 h to 36 h may 
be considered. As previously elucidated, extension of 
the dosing interval is not expected to negatively affect 
drug’s efficacy.
The calculated values  of the pharmacokinetic 
parameters (CL, Vd, t1/2) for each of the patients were 
assessed, and they are comparable with the results 
of previous studies [7,17-19]. Statistical difference in 
pharmacokinetic parameters was not detected between 
groups, confirming linear pharmacokinetics of genta-
micin. However, wide inter-individual variability was 
observed. In the study by Mannan et al, difference in 
the renal function between pre- and full-term neonates 
was explained by gestational age [9], while Nielsen et 
al. showed that bodyweight, and both gestational and 
postnatal age were found to be main factors contribut-
ing to variability in gentamicin CL in neonates [15]. 
Furthermore, Knight et al, revealed significant difference 
between the mean trough concentrations assessed on 
day 2 versus days 3 or 4 [20]. Due to small sample size, 
multiple regression analysis could not be performed in 
our study in order to investigate the impact of gesta-
tional and postnatal age or bodyweight, on gentamicin 
pharmacokinetics. 
In this study a rather small number of patients was 
included. Additionally, information regarding the local 
sensitivity of isolated microorganisms is necessary, 
and would be useful for an in-debth analysis. However, 
clinical studies including neonatal patients are always 
a great benefit to the scientific community and clinical 
practice due to wide spread use of genatmicin in the 
neonatal population. 
Table 2. Gentamicin concentrations and pharmacokinetic param-
eters
PARAMETERS
mean value ± 
standard deviation
Cpeak [mg/l]
group I - on 12 h 7.27 ± 1.27
group II – on 24 h 15.53 ± 5.29
Ctrough [mg/l]
group I - on 12 h 1.90 ± 1.08
group II – on 24 h 1.47 ± 0.58
Vd [l/kg] 0.52 ± 0.47
CL [l/h/kg] 0.055 ± 0.036
β[h-1] 0.1339 ± 0.1144
t1/2 [h] 6.89 ± 3.21
Cpeak peak concentration; Ctrough trough concentration; Vd volume of 
distribution; CL clearance; β elimination rate constant; t1/2 elimination 
half-life.
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The results of this study indicate that significantly 
higher peak and a tendency of lower trough gentamicin 
concentrations were achieved after once daily regimen 
comparing with twice daily dosing. Furthermore, esti-
mated pharmacokinetic parameters  show considerable 
inter-individual variability, and highlight the need for rou-
tine therapeutic drug monitoring in order to individually 
optimize the gentamicin dosing regimen.
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